Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

B-Lymphoblastic Leukemia/Lymphoma

For B-lymphoblastic leukemia, there is at least 25% blasts in the bone marrow aspirate. 

If there is suspicion of this disease, a university hospital should be contacted immediately for emergency help/evaluation and treatment. Special requirements are necessary for diagnostics, including immunophenotyping and cytogenetic examinations. 

About 50% of patients are cured, and prognosis is far better for younger patients than older.


B-lymphoblastic lymphoma (with < 25% blasts in bone marrow) is rare and should be treated from the protocol for B-lymphoblastic leukemia. 

Treatment consists of intensive chemotherapy as for acute lymphatic leukemia.

Selected subgroups with negative prognostic parameters or poor response during ongoing primary treatment should be considered for allogeneic stem cell transplantation in the first remission. 

First line treament is usually the traditional ALL protocol after the Hammersmith 82 regimen.

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2017